Clinical trials: Chronic Graft vs. Host Disease, open to volunteers
Chronic Graft Versus Host Disease
A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)
This is an interventional phase IV clinical study which is single-arm study for assessing the safety of belumosudil in Indian patients who are12 years and older.
- Trial name
- NCT07135973
- Testing
- Belumosudil
- Volunteers
- 26 people
- Sponsor
- Sanofi
Chronic Graft vs. Host Disease
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
Background: Chronic graft-versus-host disease (cGVHD) is a multi-organ alloimmune and autoimmune disorder that occurs following allogeneic hematopoietic stem cell transplantation (alloHSCT).
- Trial name
- NCT00092235
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease
Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
This clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (GVHD) in patients undergoing an allogeneic hematopoietic cell…
- Conditions
- Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
- Trial name
- NCT07535008
- Testing
- Dental Cleaning, Dental Plaque sampling
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Fred Hutchinson Cancer Center
GVHD (Acute or Chronic)
A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graft-versus-Host Disease After Haploidentical Stem Cell Transplantation in Children
This study is a single arm, open label Phase Ib clinical trial, consisting of two parts: the first part is a safety introduction trial, and the second part is a dose escalation trial.
- Trial name
- GVHD (NCT07350057)
- Testing
- 1mg /kg VIC-1911
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID)
Evaluation of Patients With Immune Function Abnormalities
This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation.
- Conditions
- Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID), Leukocyte Adhesion Deficiency 1 (LAD), Graft Versus Host Disease (cGvHD)
- Trial name
- NCT00128973
- Where
- United States
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host Disease
This clinical trial tests a mindfulness intervention, consisting of group sessions and an individual session, using mindfulness based stress reduction techniques, to reduce patient reported symptoms for patients with chronic…
- Conditions
- Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT07733141
- Testing
- Biospecimen Collection, Mindfulness Relaxation, Survey Administration
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- City of Hope Medical Center
Chronic Graft-versus-host-disease
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
- Trial name
- AXemplify-357 (NCT06585774)
- Testing
- INCA034176, Corticosteroids
- Where
- 131 sites in United States, Australia and 11 more
- Volunteers
- 240 people
- Sponsor
- Incyte Corporation
Chronic Graft-versus-host-disease
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
This study will be conducted to compare Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
- Trial name
- NCT07124078
- Testing
- INCA034176, Best available Treatment (BAT)
- Where
- 41 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Incyte Corporation
Chronic Graft Versus Host Disease
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
This phase II trial tests how well axatilimab works in treating patients with thickening or hardening (sclerosis) of the skin related to chronic graft-versus-host disease after a donor stem cell transplant.
- Trial name
- NCT07011810
- Testing
- Axatilimab, Biospecimen Collection, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Graft Versus Host Disease
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
This is an open-label, single group, Phase 1/2, 1-arm study for treatment of children aged 1 to <18 years with active moderate-to-severe cGVHD that is refractory to or recurred after at least 2 prior lines of systemic therapy for…
- Trial name
- schoolROCK (NCT07116031)
- Testing
- Belumosudil
- Where
- 35 sites in United States, Belgium and 11 more
- Volunteers
- 37 people
- Sponsor
- Sanofi
Chronic Graft vs. Host Disease, GVHD
Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease
Chronic graft-versus-host disease (cGVHD) is a condition that can develop after a stem cell transplant. It occurs when donor immune cells attack the body's tissues.
- Conditions
- Chronic Graft vs. Host Disease, GVHD, cGVHD, Graft Versus Host Disease in Skin
- Trial name
- NCT07728708
- Testing
- Axatilimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Acute Leukemia in Remission, Myelodysplastic Syndromes
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease…
- Conditions
- Acute Leukemia in Remission, Myelodysplastic Syndromes, Myeloproliferative Syndrome, Hodgkin Lymphoma
- Trial name
- TMF-Allo (NCT04935684)
- Testing
- Fecal Microbiota Transplantation
- Where
- 20 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Clermont-Ferrand
Chronic Graft Versus Host Disease
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease.
- Trial name
- NCT05996627
- Testing
- Belumosudil, Biospecimen Collection, Electronic Health Record Review
- Where
- 5 sites in United States
- Volunteers
- 82 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Graft Versus Host Disease
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Participants will be randomized 1:1 to receive either belumosudil or Best Available Therapy (BAT), with stratification based on baseline cGVHD severity as defined by the 2014◦NIH consensus criteria (moderate versus severe), use…
- Trial name
- NCT07771439
- Testing
- Belumosudil, Best available therapy (BAT)
- Volunteers
- 356 people
- Sponsor
- Sanofi
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Chronic Graft Versus Host Disease in Eye
Observational Cohort Study on Ocular Chronic Graft-Versus-Host Disease
This study is a multicenter, prospective, observational cohort study designed to enroll a total of 340 patients undergoing allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT07794800
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Ruijin Hospital
Chronic Graft Versus Host Disease
Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
The primary objective of the study is to evaluate belumosudil pharmacokinetics of whole tablets and crushed tablets suspended in water in patients suffering from chronic graft-versus-host disease (cGVHD).
- Trial name
- NCT07127926
- Testing
- Belumosudil
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Graft Versus Host Disease
A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
This is an open, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets in patients with chronic graft-versus-host disease
- Trial name
- NCT06300320
- Testing
- TQ05105 tablets
- Where
- 12 sites in China
- Volunteers
- 65 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Ocular Graft-versus-host Disease
Electrostimulation Study for Ocular Graft vs. Host Disease
This trial is testing to see if electrostimulation treatment (ET) will be effective in treating those with ocular Graft vs. Host Disease.
- Trial name
- NCT07166848
- Testing
- Electrodes with Currents, Electrodes without Currents
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Zhonghui K. Luo, MD, PhD
Chronic Graft-versus-host Disease (cGVHD)
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
Allogeneic transplant is potentially curative for hematological malignancies but its use is limited by the development of GVHD. Ruxolitinib now has FDA approval for treatment of chronic GVHD that has failed 1-2 prior lines of…
- Trial name
- NCT06660355
- Testing
- Ruxolitinib, Prednisone
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute